Do Opioids Have a Role in the Management of Knee and Hip Osteoarthritis?
Researchers assessed pain relief and functional improvement in patients receiving opioids for knee or hip osteoarthritis.
Musculoskeletal Pain
FDA Approves Orphengesic Forte for Pain Management
The FDA has approved the supplemental Abbreviated New Drug Application (sANDA) for Orphengesic Forte.
Evidence Supporting Use of Compounded Topical Pain Creams Limited
“In context of the recent rise in supply and demand of compounded preparations, lack of evidence regarding systemic absorption of ingredients used in compounded topical pain creams gives rise to a substantial public health concern,” the authors concluded.
MPR Weekly Dose Podcast Episode 34
This week we cover the latest COVID-19 developments including a triple antiviral therapy that looks promising, Emergency Use Authorizations granted to diagnostics and critical meds, Moderna’s investigational vaccine gets Fast Tracked, and the National Institute of Health’s remdesivir plus baricitinib trial.
Nonopioid Drug Therapies Evaluated for Chronic Pain
Various electronic databases were accessed to obtain randomized controlled trials (RCTs) evaluating nonopioid agents in chronic pain patients. The review focused on 7 chronic pain conditions, including neuropathic pain, fibromyalgia, osteoarthritis, inflammatory arthritis, low back pain, chronic headache, and sickle cell disease.
FDA Approves OTC Combination of Ibuprofen and Acetaminophen
The FDA has approved Advil Dual Action with Acetaminophen (GlaxoSmithKline), the first over-the-counter (OTC) fixed-dose combination therapy containing ibuprofen and acetaminophen for the temporary relief of minor aches and pains due to headache, backache, muscular aches, toothache, menstrual cramps, and minor pain of arthritis. Each caplet contains 125mg of Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID)…
FDA to Review Tanezumab, a Potential First-in-Class Treatment for Osteoarthritis Pain
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for tanezumab (Pfizer and Lilly) 2.5mg administered subcutaneously for moderate to severe osteoarthritis (OA) pain.
MPR Weekly Dose Podcast Episode 22
This week on the pod we cover the withdrawal of Belviq, the weight-loss drug, from the market; the over-the-counter approval of diclofenac gel and olopatadine eye drops; a new contraceptive transdermal patch; a possible vaccine for ricintoxin; and new research finds that hundreds of sellers are using Craigslist to sell prescribing medications.
FDA Clears OTC Electromagnetic Pulse Therapy for Musculoskeletal Pain Relief
The over-the-counter (OTC), drug-free medical device, ActiPatch®, has obtained a new 510(k) clearance from the Food and Drug Administration (FDA) for the adjunctive treatment of musculoskeletal pain.
MPR Weekly Dose Podcast: Episode 17
In our first episode of 2020 we cover new management guidelines in osteoarthritis; Recommendations for the use of testosterone therapy; The best diets for 2020; Two drug recalls; And a new drug approved for the treatment of migraines.
